Mutation profiles in long-term survivors with pulmonary metastases from pancreatic ductal adenocarcinoma

Pancreatology ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. S83
Author(s):  
Masato Ono ◽  
Toru Namamura ◽  
Toshiaki Shichinohe ◽  
Keisuke Okamura ◽  
Takhiro Tsuchikawa ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Pulmonary Metastases ◽  
Ductal Adenocarcinoma ◽  
Long Term Survivors

scholarly journals A Retrospective Analysis of Long-Term Survivors with Metastatic Pancreatic Ductal Adenocarcinoma

2013 ◽  
Vol 24 ◽  
pp. ix47
Author(s):  
H. Hayashi ◽  
S. Kondo ◽  
S. Shiba ◽  
Y. Sakamoto ◽  
C. Morizane ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Retrospective Analysis ◽  
Ductal Adenocarcinoma ◽  
Long Term Survivors

scholarly journals Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
S. A. Safi ◽  
N. Lehwald-Tywuschik ◽  
A. Rehders ◽  
G. Fluegen ◽  
L. Haeberle ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Pulmonary Metastases ◽  
Hepatic Metastases ◽  
Disease Free Survival ◽  
Venous Invasion ◽  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas ◽  
Isolated Local Recurrence ◽  
Long Term Survivors

Abstract Background Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and post relapse survival (PRS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases. Methods Patients with isolated resectable local recurrence, metachronous hepatic or pulmonary metastases were included for survival analyses. PRS of surgically treated patients (local (n = 11), hepatic (n = 6) and pulmonary metastases (n = 9)) was compared to conservatively treated patients (local (n = 17), hepatic (n = 37) and pulmonary metastases (n = 8)). Results Resected PDAC patients suffering from isolated metachronous hepatic metastases initially had a higher T-stage and venous invasion (V1) compared to the other patients. DFS in the metachronous pulmonary metastases group was longer compared to DFS of the hepatic metastases and local recurrence groups. Surgical resection significantly improved PRS in patients with local recurrence and pulmonary metastases, when compared to patients receiving chemotherapy alone. Very-long term survivors (> 5 years) were detected following secondary resection of local recurrence and 45% of these patients were still alive at the end of our study period. Conclusion Although DFS in PDAC patients suffering from isolated local recurrence was dismal and comparable to that of patients with isolated hepatic metastases, very-long term survivors were present only in this group. These results indicate that a surgical approach for isolated local recurrence, if anatomically possible, should be considered.

scholarly journals Long‐Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis

2019 ◽  
Vol 24 (12) ◽  
pp. 1543-1548 ◽  
Author(s):  
Pauline Rochefort ◽  
Audrey Lardy‐Cleaud ◽  
Matthieu Sarabi ◽  
Françoise Desseigne ◽  
Anne Cattey‐Javouhey ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Matched Pair ◽  
Matched Pair Analysis ◽  
Long Term Survivors ◽  
Pair Analysis

Long-term survivors after pancreatic ductal adenocarcinoma resection: An actual 5-year analysis of overall and post-recurrence survival

Pancreatology ◽  
2021 ◽  
Vol 21 ◽  
pp. S84
Author(s):  
G. Belfiori ◽  
S. Crippa ◽  
F. Aleotti ◽  
G. Gasparini ◽  
D. Tamburrino ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Long Term Survivors

scholarly journals Site of Relapse of Ductal Adenocarcinoma of the Pancreas Affects Survival after Multimodal Therapy

2020 ◽  
Author(s):  
Sami Alexander Safi ◽  
Nadja Lehwald ◽  
Alexander Rehders ◽  
Georg Fluegen ◽  
Lena Julia Haeberle ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Pulmonary Metastases ◽  
Hepatic Metastases ◽  
Disease Free Survival ◽  
Venous Invasion ◽  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas ◽  
Isolated Local Recurrence ◽  
Long Term Survivors

Abstract Background: Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and post relapse survival (PRS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases.Methods: Patients with isolated resectable local recurrence, metachronous hepatic or pulmonary metastases were included for survival analyses. PRS of surgically treated patients (local (n=11), hepatic (n=6) and pulmonary metastases (n=9)) was compared to conservatively treated patients (local (n=17), hepatic (n=37) and pulmonary metastases (n=8)).Results: Resected PDAC patients suffering from isolated metachronous hepatic metastases initially had a higher T-stage and venous invasion (V1) compared to the other patients. DFS in the metachronous pulmonary metastases group was longer compared to DFS of the hepatic metastases and local recurrence groups. Surgical resection significantly improved PRS in patients with local recurrence and pulmonary metastases, when compared to patients receiving chemotherapy alone. Very-long term survivors (>5 years) were detected following secondary resection of local recurrence and 45% of these patients were still alive at the end of our study period.Conclusion: Although DFS in PDAC patients suffering from isolated local recurrence was dismal and comparable to that of patients with isolated hepatic metastases, very-long term survivors were present only in this group. These results indicate that a surgical approach for isolated local recurrence, if anatomically possible, should be considered.

scholarly journals Site of Relapse of the Ductal Adenocarcinoma of the Pancreas affects Survival after Multimodal Therapy

2020 ◽  
Author(s):  
Sami Alexander Safi ◽  
Nadja Lehwald ◽  
Alexander Rehders ◽  
Lena Julia Haeberle ◽  
Verena Keitel ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Pulmonary Metastases ◽  
Hepatic Metastases ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Free Survival ◽  
Adenocarcinoma Of The Pancreas ◽  
Isolated Local Recurrence ◽  
Long Term Survivors

Abstract Background The ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unclear, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and relapse specific survival (RSS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases. Methods Patients with isolated resectable metachronous disease of either local recurrence, hepatic or pulmonary metastases were included for survival analyses. RSS of surgically treated patients (local (n = 11), hepatic (n = 6) and pulmonary metastases (n = 11)) were compared to conservative treated patients (local (n = 20), hepatic (n = 49) and pulmonary metastases (n = 14)). Results Patients with isolated metachronous hepatic metastases showed a higher T-stage and hepatic M-stage in the primary staging of the previous resected PDAC when compared to the other patients. DFS before diagnosed pulmonary metastases was longer compared to DFS before diagnosed hepatic metastases or local recurrence. Surgical resection only significantly improved RSS in patients with local recurrence or pulmonary metastases, when compared to patients after chemotherapy. Long-term survivors (> 5 years) were only detected after surgery for isolated local recurrence and 45% of these patients were still alive in our study. Conclusion Although DFS before diagnosed isolated local recurrence was dismal and comparable to patients with isolated hepatic metastases, long-term survivors were only detected in this group, recommending a surgical approach if resectability is provided.

scholarly journals Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol 21 (5) ◽  
pp. 1779 ◽  
Author(s):  
Maximilian Brunner ◽  
Katharina Maier ◽  
Petra Rümmele ◽  
Anne Jacobsen ◽  
Susanne Merkel ◽  
...  
Keyword(s):  
Overall Survival ◽  
B Cells ◽  
B Cell ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Cell Aggregates ◽  
Tumor Infiltration ◽  
Long Term Survivors

Patients with pancreatic ductal adenocarcinoma (PDAC) normally have a poor long-term prognosis. However, some rare cases of long-term survivors have been reported. The tumor microenvironment, consisting of cellular and stromal components, possibly plays an important role and might influence prognosis. In this context, the role of tumor-infiltrating B-cells and its impact on the survival in patients with PDAC remains controversial. We therefore aimed to assess the prognostic value of CD20-positive B-cells and CD20-positive B-cell aggregates as well as CD138, IgM, Pax5, and Ki67 on the survival of patients with PDAC using immunohistochemistry of FFPE pancreatectomy tissue sections from patients that underwent primary surgery for pT3- and R0-pancreatic adenocarcinoma between 1995 and 2016. Patients with PDAC were matched and grouped in 16 long-term-survivors (LTS, median overall survival (OS): 96 months [range: 61–177 months]) and 16 short-term-survivors (STS, median OS: 16 months [range: 7–32 months]). CD20-positive B-cells and B-cell aggregates in the tumor infiltration zone were significantly upregulated in the LTS-group compared to the STS-group (p = 0.0499 respectively p = 0.0432). Regarding the entire patient cohort (n = 32) CD20 positive B-cell aggregates in the tumor infiltration zone were an independent prognostic marker for overall survival in multivariate analysis (HR 9.2, CI 1.6–51.4, p = 0.012). These results underline the importance of tumor-associated B-cells for prognosis of patients with PDAC. The detailed role of B cells in the pathomechanism of PDAC should be further investigated for predicting outcome, identifying appropriate treatment regimens, and developing novel therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document